ALB and metabolic syndrome: We postulate that MetS-induced gut barrier dysfunction (29) may alter chemotherapeutic agent bioavailability, while elevated free fatty acids compete with albumin-bound chemotherapeutic agents (e.g., taxanes, irinotecan) for protein binding (30)—mechanisms requiring validation through pharmacokinetic studies.